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Abstract
Background: Hepatitis B Virus (HBV) is one of the most serious infectious diseases and represents a major global health issue worldwide. It can be
transmitted vertically and horizontally through contact with infected blood or body fluids. More attention to HBV infection in pregnancy is needed
due to high risk of chronicity when transmitted to infants during delivery.
Objectives: A comprehensive review of the HBV prevalence rate in pregnant females taking into account different geographical areas and socio-
economic status is still lacking. This would be of crucial importance for HBV prevention and control programs. As such, this systematic review and
meta-analysis was conducted focusing on HBV prevalence rate in pregnant females from different parts of the world.
Methods: Different electronic databases, including Embase, PubMed/MEDLINE, Scopus, and ISI/Web of Science were searched from January 1st 2000
to July 31st 2016, using relevant keywords, such as “prevalence” or “seroprevalence” or “epidemiology” and “pregnancy” or “pregnant” or “antenatal”
in combination with “hepatitis B virus” or “HBV” with no language restrictions. The study protocol of this systematic review was deposited at the
“International Prospective Register of Systematic Reviews” and registered as CRD42016041985.
Results: After scrutinizing all the extant scholarly literature from 2000 to 2016, this study found 222 relevant articles. The overall HBV prevalence
rate in pregnant females worldwide was estimated using a random-effect model, giving a value of 3% (95% confidence interval or CI 2% - 4%). Hetero-
geneity between studies was significantly high (I2 = 99.9%, P < 0.0001). The clinical and epidemiological burden was higher in developing countries.
Conclusions: This suggests that despite the recent scientific advancements and the clinical progress that has occurred in anti-viral therapy, HBV still
represents a major issue worldwide, especially in underdeveloped countries. The key strategies for preventing transmission from pregnant females
to their fetuses are through early birth dose and infant vaccination, as well as by the use of hepatitis B immunoglobulin (HBIG) and the screening
and diagnosis of mothers at high risk and the subsequent use of anti-viral agents during pregnancy in order to reduce maternal DNA concentrations
down to undetectable concentrations. Health authorities should effectively implement these approaches to better control HBV in pregnancy.
Keywords: Hepatitis B Virus, Pregnancy, Systematic Review and Meta-Analysis, Vaccines and Vaccination
1. Background
According to the world health organization (WHO), ap-
proximately 240 million people worldwide are affected by
chronic hepatitis (1, 2). Each year, more than 686,000 pa-
tients obtain HBV-related cirrhosis and die of liver cancer
(1). In addition, HBV challenges the National health sys-
tems and imposes a significant economic burden. Some of
the direct costs include the delivery of diagnostic services,
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hospitalization, and the administration of drugs, whilst
indirect costs are generated by the loss of quality of life
and reduced productivity. The HBV prevalence rate signif-
icantly varies among different regions: It is less than 1%
in America and Western Europe, whilst the highest preva-
lence rate is 5% to 10% and can be observed in East Asia
and sub-Saharan Africa. A rate between 2% and 5% could
be found in the Middle East and the Indian subcontinent
(2-4).
Hepatitis B Virus can be transmitted both vertically
and horizontally through contact with infected blood or
body fluids. Risk factors for developing HBV infection in-
clude having unprotected sex with multiple sexual part-
ners or with infected individuals, being a man, who has
sex with other men, sharing needles during intravenous
(IV) drug use, living with infected individuals, being occu-
pationally exposed to blood, and travelling to regions, in
which HBV is endemic, among others (5).
Hepatitis B Virus should be seriously taken into con-
sideration during pregnancy, as the infection can have
clinical implications for both the mother and the fetus
(6, 7): without prophylaxis, the risk of vertical transmis-
sion is, indeed, high, ranging from 10% to 40% in HBsAg-
positive HBeAg-negative mothers to 70% in HBsAg- and
HBeAg-positive mothers (8). An effective vaccine is cur-
rently available, yet, unfortunately, immunization cover-
age is not very high, especially in developing countries (9).
In order to investigate the HBV prevalence rate in preg-
nant females, many studies have been conducted world-
wide. However, to the best of our knowledge, a comprehen-
sive review of the HBV prevalence rate in pregnant female
taking into account the different geographical areas and
their socio-economic status is still lacking. This would be
of crucial importance for HBV prevention and control pro-
grams. Recently, in May 2016, the world health organiza-
tion (WHO) adopted the “Global Health Sector Strategy on
Viral Hepatitis, 2016 to 2021” and one of the strategies sug-
gested was “formulating evidence-based policy and data
for action” (10).
As such, this systematic review and meta-analysis was
conducted in order to systematically collect available data
focusing on HBV prevalence rate in pregnant females
from different parts of the world. The current findings
could have important implications for health policy- and
decision-makers as well as for the stakeholders to better
understand the current status of HBV in pregnant females.
2. Methods
2.1. Information Sources and Search
Different electronic databases including Embase,
PubMed/MEDLINE, Scopus and ISI/Web of Science were
searched from January 1st 2000 to July 31st 2016, using
relevant keywords such as “prevalence” or “seropreva-
lence” or “epidemiology” and “pregnancy” or “pregnant”
or “antenatal” in combination with “hepatitis B virus”
or “HBV” with no language restrictions. Four authors
independently screened titles and abstracts of studies and
checked whether they met the inclusion criteria, selecting
potentially eligible studies. Any disagreements between
reviewers were resolved after discussion involving a fifth
referee. This study also consulted the reference list of each
potentially relevant study as well as related studies and
extant reviews/overviews in order to increase the chance
of obtaining all the pertinent studies.
2.2. Eligibility Criteria
Inclusion criteria, according to the PICO criteria, were
as follows: i) population-based study reporting HBV preva-
lence rate in pregnant females with no age limit; ii) stud-
ies using a standardized/validated diagnostic test for the
detection of HBV in pregnant females; iii) prevalence rate
clearly stated or, if missing, appropriate and relevant quan-
titative information in order to calculate the prevalence
data; iv) full-text available or abstract providing mini-
mum relevant quantitative information; and v) primary
research studies published in peer-reviewed journals be-
tween January 2000 and July 2016, reporting HBV preva-
lence rate in pregnant females.
Concerning the exclusion criteria, the research did
not select studies with pregnant females from high risk
groups, such as drug abusers, Human Immunodeficiency
Virus (HIV)-positive pregnant females, females attending
sexually-transmitted-disease (STDs) clinics, sex workers
and dialysis patients. Further exclusion criteria were: i)
studies with unclear prevalence data and/or methodologi-
cal errors, and ii) non primary research studies.
The methodological quality of the included studies
was evaluated using the Newcastle-Ottawa scale (NOS) (11).
Two authors independently performed the quality assess-
ment and any disagreements between them were resolved
by discussion and/or involving a third person as a judge.
Up to four stars were attributed on the basis of selection,
up to two stars for study comparability and up to three
stars on the basis of the study outcome(s). Studies that re-
ceived two or three stars and two stars for the selection and
comparability items, respectively, were considered as af-
fected by a low or moderate risk of bias, while studies that
received a star for the selection, comparability and out-
come(s) items or achieved null score in all sections were
characterized by a high risk of bias.
From studies meeting the inclusion criteria, the fol-
lowing data were extracted by two independent reviewers:
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namely, surname of the first author, year of study publica-
tion, number of women with positive hepatitis B surface
antigen (HBsAg), study type, country, sample size, mean
age or age range of participants, and HBV prevalence rate.
Any disagreements were resolved by discussion. The main
outcome of the present study was the HBV prevalence rate
in pregnant females. This study was carried out according
to the “Preferred Reporting Items for Systematic reviews
and Meta-Analysis” (PRISMA) guidelines (12). The study pro-
tocol of this systematic review was deposited in the “Inter-
national Prospective Register of Systematic Reviews” and
registered as CRD42016041985 (13).
On the basis of the data provided by the included stud-
ies, the pooled prevalence rate with 95% confidence inter-
val (CI) was calculated using the DerSimonian and Laird
random-effect model (14, 15). Heterogeneity was estimated
carrying out the I2 test (16). In order to evaluate the a pri-
ori effects of the pooled HBV prevalence rate in pregnant
females, stratified analyses were performed based on fac-
tors such as socio-economic status of the study country
(countries classified in developed or developing countries
according to the International Monetary Fund or IMF), the
year of publication of studies, the quality of studies, the ge-
ographic areas as classified by the WHO, and mean age or
age range of participants (17).
In order to investigate the causes of the heterogene-
ity between studies, meta-regression analyses were per-
formed based on the sample size and year of publication.
To assess the robustness of results, a sensitivity analysis
was carried out (18). Studies were ranked according to
year of publication and sample size and cumulative meta-
analysis was performed to evaluate the impact of these fac-
tors (19). Publication bias was determined both visually, in-
specting the eventual asymmetry of the funnel plot, and by
carrying out the Egger’s test (20).
The relationship between pooled HBV prevalence rate
in pregnant females and the human development index
(HDI) for each studied country was estimated with linear
meta-regression. The HDI is a composite index that com-
bines different measures and indicators, such as life ex-
pectancy, educational index, and Gross National Income
per capita (GNP) as computed by the united national devel-
opment program (UNDP).
For all the statistical analyses, figures with a P value of <
0.05 were considered as statistically significant. All statis-
tical analyses were carried out using the open-source soft-
ware R (version 3.3.1, the R Foundation for Statistical Com-
puting, https://www.R-project.org/) with the Meta package.
3. Results
3.1. Study Flow-Chart and Characteristics of the Included Stud-
ies
Overall, 3149 studies were identified in the initial
search, then after removing duplicate items, 2564 studies
were assessed and screened regarding the basis of their ti-
tle and abstract. Finally, 223 studies met the inclusion crite-
ria, with a total sample size of 40, 958, and 838 pregnant fe-
males (Figure 1). The main characteristics of included stud-
ies are reported in supplementary file Appendix 1, to which
the reader is referred for further details.
According to the WHO geographical regions, 79, 46, 30,
28, 23, and 16 studies were carried out in African, European,
Eastern Mediterranean, South East Asiatic, American, and
Western Pacific areas, respectively.
3.2. Risk of Bias of Included Studies
The quality assessment using the NOS instrument
showed that 152 and 71 studies were characterized by a
low and high risk of bias, respectively. In particular, 174,
195, and 87 studies were characterized by low quality in
terms of selection, comparability and outcomes, respec-
tively. Overall, 13, 15 and 21 presented medium quality con-
cerning selection, comparability and outcomes, respec-
tively, whilst 35, 12 and 14 exhibited high quality, for selec-
tion, comparability, and outcomes, respectively.
3.3. Pooled Prevalence Rate of Hepatitis B Virus in Pregnancy
The overall HBV prevalence rate in pregnant females
worldwide, estimated using a random-effect model, was 3%
[95%CI 2% - 4%]. Heterogeneity between studies was signif-
icantly high (I2 = 99.9%, P < 0.0001) due to epidemiologi-
cal differences among populations in terms of HBV preva-
lence, risk factors, and health policies.
3.4. Results of Sub-Groups Analysis of Included Studies
Sub-group analyses pooling HBV prevalence rate in
pregnant females based on the study country, WHO areas,
IMF classification, quality of the published studies, and
study design are shown in Table 1.
3.5. Results of Sensitivity and Cumulative Analyses
To ensure the robustness of the results, before and af-
ter sensitivity analyses were carried out, showing a statis-
tically unchanged prevalence of 3% [95%CI 2 to 4%]. Also,
cumulative meta-analyses, based on the ranking of the
sample-size and the year of publication of studies, were
conducted. The results did not change statistically.
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Studies included in 
quantitative synthesis 
(meta-analysis)  
(n = 222) 
Studies included in 
qualitative synthesis
(n = 222)
Full-text articles excluded 
(n = 354) 
Full-text articles assessed 
for eligibility  
(n = 577 )
Records excluded  
(n = 1,987) 
Records screened  
(n = 2,564) 
Records after duplicates removed  
(n = 2,564) 
Additional records identified 
through other sources
(n = 347 )
Records identified through database 
searching




























Figure 1. Flow-Chart of the Current Systematic Review and Meta-Analysis, Showing Studies Search and Selection
3.6. Meta-Regression Analyses
The findings of the meta-regression analyses based on
year of publication and sample-size of the included studies
are shown in Table 2 and Figure 2.
3.7. Publication Bias
Publication bias analysis showed evidence of publica-
tion bias (Egger’s test P = 0.000), as shown in Figure 3.
3.8. Relationship between Hepatitis B Virus prevalence and Hu-
man Development Index
This research found a statistically significant relation-
ship between the pooled HBV prevalence in pregnant fe-
males and the HDI of each study country (R = -0.12132, P <
0.000) (Figure 4).
4. Discussion
Despite recent scientific advancements and clinical
progress in anti-viral therapy, HBV still represents a ma-
jor issue worldwide, especially in developing countries (21,
22). The current study has found a pooled HBV prevalence
rate of 3% [95%CI 2% - 4%] among pregnant females world-
wide.
Generally speaking, HBV vaccination represents an ef-
fective tool for reducing HBV-related clinical and epidemi-
ological burden. Specifically, focusing on HBV in preg-
nancy, this infection is particularly unique and challeng-
ing. The key strategies for preventing transmission from
pregnant females to their fetuses are by early birth dose
and infant vaccination, as well as by the use of Hepatitis B
Immunoglobulin (HBIG) and the screening and diagnosis
of mothers at high risk and the subsequent use of anti-viral
agents (such as nucleoside/nucleotide analogues) during
pregnancy in order to reduce maternal DNA concentra-
tions to undetectable concentrations (23). Hepatitis B
Virus vaccines in pregnancy have been proven safe, with no
side-effects in newborns, since no congenital defects or ab-
normal developmental patterns have been observed. On
one hand, HBV immunization during pregnancy is tech-
nically and logistically challenging in that the classical
schedule (at 0, 1, and 6 months) is difficult to complete
given the limited gestational time. On the other hand, ac-
celerated schedules (at 0, 1, and 4 months) have shown
an adequate immunological and protective profile. Intra-
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Table 1. Results of Sub-Group Analyses
Variables Number of Studies Number of Participants Poled Prevalence Rate (95% CI) I2 P Value
Continent
Africa 81 79,450 6 (5 - 7) 96.4 < 0.000
Asia 78 490,372 3 (2 - 3) 99.5 < 0.000
Europe 37 1,051,387 1 (1 - 2) 99.6 < 0.000
South America 19 142,731 1 (0 - 2) 99.6 < 0.000
North America 4 39,177,247 0 (0 - 1) 99.8 < 0.000
Oceania 3 17,651 2 (2 - 2) 0 0.78
Country socio-economic status
Developing 156 478,118 4 (3 - 4) 98.5 < 0.000
Developed 66 40,480,720 1 (1 - 2) 100 < 0.000
Risk of bias
Low risk 151 40,665,166 3 (2 - 4) 99.9 < 0.000
High risk 71 293,672 3 (2 - 4) 99.2 < 0.000
Year of publication
2000 - 2005 24 262,676 2 (1 - 3) 99.7 < 0.000
2006 - 2010 54 309,111 3 (2 - 3) 99.5 < 0.000
2011 - 2016 144 40,387,051 3 (2 - 4) 99.9 < 0.000
WHO regional classification
AFRO 79 76,950 6 (5 - 7) 96.3 < 0.000
SEARO 28 196,904 2 (1 - 3) 99.1 < 0.000
EURO 46 1,104,262 1 (1 - 2) 99.5 < 0.000
EMRO 30 130,190 2 (2 - 3) 95.4 < 0.000
PAHO 23 39,319,978 1 (0 - 1) 99.9 < 0.000
WPRO 16 130,554 6 (5 - 8) 99.2 < 0.000
Type of study
Case – control 5 1,995 5 ( 3 - 9) 80.8 0.0003
Cohort 2 6,295 7 ( 7 - 8) 0 0.3642
Cross – sectional 188 1,508,658 3 (3 - 4) 99.5 0.0001
Prospective 7 18,795 3 (2 - 6) 96.3 0.0001
Retrospective 20 39,423,095 1 (0 - 3) 100 0.0001
Table 2. Results of Meta-Regression Analyses
Variable Estimated Standard Error Z Value P Value Lower CI95% Upper CI95%
Year 0.0277 0.0332 0.8341 0.4042 -0.0374 0.0928
Sample-size -0.000 0.000 -2.3775 0.0174 -0.0000 -0.0000
dermal route is another promising approach that could be
used in high-risk patients, such as subjects with celiac dis-
ease (24) as well as in non-responder individuals in order
to accelerate the formation of an immunological response
and exhibit a protective and adequate safety profile even
in pregnancy (25). However, different surveys have under-
lined low maternal vaccine uptake and have found that
many misconceptions and prejudices about HBV in preg-
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Figure 2. Results of the Meta-Regression Analyses Based on the Sample-Size and Year of Publication of the Included Studies
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Figure 3. Publication Bias Analyses (Funnel Plot and Egger’s Test)
nancy do exist. Educational interventions have focused
on benefits to both maternal and neonatal health, which
should be made in order to increase maternal knowledge
related to HBV for improving vaccine confidence and, sub-
sequently, vaccine coverage (7).
Furthermore, infant vaccination is particularly recom-
mended in countries characterized by high HBV endemic-
ity. Concerning anti-virals, according to a recently pub-
lished meta-analysis, pharmacological treatment is able to
effectively reduce peri-natal or mother-to-child transmis-
sion, as defined by infant HBSAg seropositivity (risk ratio
or RR = 0.3 [95%CI 0.2 - 0.4]) or infant HBV DNA seroposi-
tivity (RR = 0.3 [95%CI 0.2 - 0.5]) at 6 to 12 months, with no
side-effects (in terms of congenital malformation rate, pre-
maturity rate, and Apgar score) (26).
Combined, multifaceted strategies integrating screen-
ing, prevention, and treatment have been proven to be
effective in reducing and mitigating HBV-related burden
(27-30). As such, health authorities should effectively im-
plement programs and approaches to increase maternal
health literacy and to better control HBV in pregnancy. Fur-
thermore, researchers should design high-quality investi-
gations, covering this topic, which is often underestimated
and overlooked in the extant literature.
Decision- and policy-makers should take into account
the context and the setting for better design and imple-
mentation of ad hoc interventions and strategies. The find-
ings of this study showed, indeed, a significant relation-
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Figure 4. Correlation Between the Pooled Hepatitis B Virus Prevalence in Pregnant
Females and the Human Development Index for Each Study Country
ship between HDI and prevalence of HBV among pregnant
females (P < 0.05). Furthermore, HDI, as introduced by
the UND, is a standardized summary measure of social and
economic development of countries (31). In many studies,
HDI has been found to be a robust, reliable predictor of
maternal and infant mortality rate, worldwide (32). In dif-
ferent studies, included in the present systematic review
and meta-analysis, maternal high educational levels cor-
related with a higher awareness of baby’s health and re-
sulted in healthier behaviors during pregnancy and deliv-
ery, such as attending primary care services and perform-
ing HBV screening (33). Low socio-economic status was sig-
nificantly associated with higher HBV prevalence rate and
lower screening adhesion among pregnant females (34,
35).
Concerning the current study, this systematic re-
view and meta-analysis, despite having different strengths
like the pre-designed protocol, comprehensive and broad
database search, use of different independent reviewers
and data extractors, and a rigorous methodological ap-
proach, had some drawbacks and limitations that should
be acknowledged. These include the high heterogeneity
between studies and the fact that approximately a third of
the included studies presented high risk of bias.
4.1. Conclusions
Our systematic review and meta-analysis has scruti-
nized all the scholarly literature from 2000 to 2016 and has
captured all the relevant studies reporting HBV prevalence
in pregnant females. This study has practical implications
for policy- and decision-makers, warranting the adoption
and implementation of ad hoc programs and strategies
based on epidemiological data and on scientific evidences.
Supplementary Material
Supplementary material(s) is available here [To read
supplementary materials, please refer to the journal web-
site and open PDF/HTML].
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